BIOMAT Database Logo BIOMAT Database Logo

Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. 1994

M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Department of Microbiology, Kanazawa Medical University, Ishikawa, Japan.

The amino-terminal portion of human cytomegalovirus glycoprotein B (HCMV-gB) was expressed as a fusion protein to analyze the neutralizing epitope recognized by human monoclonal antibody C23 and the humoral immune response to this epitope. The linear neutralizing epitope was further localized to the peptide within 17 amino acids (position 68-84) which were conserved between two HCMV laboratory strains. Ten out of 17 HCMV-seropositive human sera contained the antibody against this epitope. Although seven sera were negative for reacting with the fusion protein, the viruses isolated from the same patients retained the epitope. The immunogenicity of the epitope and the possible application of C23 human monoclonal antibody for passive immunization against HCMV infections are discussed.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B.
January 2023, PloS one,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Neutralizing antibody response to cytomegalovirus in seropositive pregnant women.
June 1991, Journal of medical virology,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
September 2018, Vaccine,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus.
August 2013, Journal of virology,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
January 2015, Journal of virology,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus.
May 1989, Journal of virology,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Anti-idiotypic mimicry of a neutralizing epitope on the glycoprotein B complex of human cytomegalovirus.
November 1993, Journal of virology,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody.
October 2014, PLoS pathogens,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.
August 2021, Journal of virology,
M Ayata, and T Sugano, and T Murayama, and D Sakamuro, and T Takegami, and Y Matsumoto, and T Furukawa
Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response.
May 2006, Journal of virology,
Copied contents to your clipboard!